 Brentuximab vedotin is an antibody-drug conjugate targeting CD30, one of surface antigens expressed in lymphoma cells. Fanale MA, et al. reported the results of a phase I study with weekly dosing of brentuximab vedotin in patients with relapsedrefractory CD30-positive hematologic malignancies Clin Cancer Res. 2012 showed tumor regression in 85 of patients. Thus, the overall objective response rate was 59 2444 including 34 n 14 of complete remissions. This study mainly included Hodgkin lymphoma n 38 and anaplastic large cell lymphoma n 5. However, its efficacy in other types of NHL has never been reported although this study enrolled one patient with peripheral T-cell lymphoma not otherwise specified PTCL-NOS. 